{
  "abstract": "Background: The clinical efficacy of therapeutic cancer vaccines is critically limited by the inefficient in vivo delivery of tumor antigens to dendritic cells (DCs), the key regulators of T-cell immunity.\n\nMethods: To address this issue, we developed a dendritic-cell-targeting adeno-associated virus (AAV) vector through rational capsid design. This was achieved by site-specifically inserting the high-affinity Clec9a-targeting peptide CBP-12, optimizing its flanking sequences, and introducing T491V/S662V gain-of-function mutations to synergistically enhance DC transduction.\n\nResults: The resulting vector, AAV2-mut-Peptide2, showed significantly improved tropism for and gene delivery efficiency to cross-presenting cDC1s in vivo . In murine models of hepatocellular carcinoma, vaccination with this platform, encoding either a model antigen (OVA) or the endogenous tumor-associated antigen GPC3, elicited a potent antigen-specific CD8+ T cell response. This response was characterized by a substantial increase in tumor-infiltrating lymphocytes, enhanced production of key effector cytokines, and consequently, potent suppression of tumor growth.\n\nConclusion: Our study establishes this engineered AAV as a versatile and potent vaccine platform that effectively targets DCs, offering a promising approach for inducing robust and adaptable anti-tumor immunity.",
  "abstract_shown": true,
  "affiliations": [
    "The Department of Gastroenterology, The First Affiliated Hospital of Henan University , , ,",
    "Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University , , ,"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 13,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Xin Wei"
    },
    {
      "affs": [
        1
      ],
      "name": "Xiang Li"
    },
    {
      "affs": [
        1
      ],
      "name": "Lixia Qi"
    },
    {
      "affs": [
        0
      ],
      "name": "Wenxuan Qiu"
    },
    {
      "affs": [
        0
      ],
      "name": "Yuxin Zhang"
    },
    {
      "affs": [
        0
      ],
      "name": "Liping Wu"
    },
    {
      "affs": [
        0
      ],
      "name": "Shutang Wei"
    },
    {
      "affs": [
        0
      ],
      "name": "Bofeng Luo"
    },
    {
      "affs": [
        0
      ],
      "name": "Menghan Shi"
    },
    {
      "affs": [
        0
      ],
      "name": "Chenhao Liu"
    },
    {
      "affs": [
        0
      ],
      "name": "Qi Yang"
    },
    {
      "affs": [
        0
      ],
      "name": "Wenyi Yang"
    },
    {
      "affs": [
        0
      ],
      "name": "Dengke Bao"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/bbgmgp4ay5f79.bib",
  "cited_by": 0,
  "doi": "10.3389/fimmu.2026.1932907",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662115/?tool=EBI",
  "id": "bbgmgp4ay5f79",
  "issns": [
    "1664-3224"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13662115",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2403|Immunotherapy and Immune Responses"
    ]
  ],
  "openalex": "W7214922691",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662115/pdf/?tool=EBI",
  "pmcid": "PMC13662115",
  "pmid": null,
  "published": "2026-09-30",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/bbgmgp4ay5f79.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:21Z",
      "native_id": "PMC:PMC13662115",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13662115"
    },
    {
      "first_seen": "2026-10-30T12:19:15Z",
      "native_id": "10.3389/fimmu.2026.1932907",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1932907/full"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:2403|Immunotherapy and Immune Responses",
      "subfield": "immunology"
    }
  ],
  "title": "Dendritic-cell-targeting adeno-associated virus as potent cancer vaccine carriers",
  "title_text": "Dendritic-cell-targeting adeno-associated virus as potent cancer vaccine carriers",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:15Z",
  "url": "https://research.draconitic.com/paper/bbgmgp4ay5f79",
  "venue": "Frontiers in immunology",
  "versions": []
}